Clinical Trials
31 trialsTINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
University of Minnesota
Resimmune®
Virogen Biotechnology Inc.
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
PEDS-PLAN
Milton S. Hershey Medical Center
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NYMC195
New York Medical College
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
National Cancer Institute (NCI)
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
RZD
Hackensack Meridian Health
QUAD
Hackensack Meridian Health
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MK-0683-103
Merck Sharp & Dohme LLC
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Medical College of Wisconsin
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy
Children's Hospital Medical Center, Cincinnati
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
The Netherlands Cancer Institute